Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn's disease

被引：0
|
作者：
Suleiman, A. [1 ]
Goebel, A. [1 ]
Bhatnagar, S. [2 ]
D'Cunha, R. [2 ]
Liu, W. [2 ]
Pang, Y. [2 ]
机构：
[1] Clin Pharmacol & Pharmacometr, AbbVie, Ludwigshafen, Germany
[2] Clin Pharmacol & Pharmacometr, AbbVie, N Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P574
引用
收藏
页码：I514 / I516
页数：4
相关论文
共 50 条
  • [21] Population pharmacokinetics and exposure-response of filgotinib in patients with moderate to severe Crohn's disease
    Sharma, Shringi
    Xin, Yan
    Gao, Yuying
    Namour, Florence
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S36 - S36
  • [22] Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study
    Hanley, Michael J.
    Larson, Thomas R.
    Diderichsen, Paul M.
    Largajolli, Anna
    Hui, Katrina
    Srimani, Jaydeep
    Wang, Bingxia
    Vorog, Alexander
    Gupta, Neeraj
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (03):
  • [23] Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
    Neha Thakre
    Ronilda D’Cunha
    Aline Goebel
    Wei Liu
    Yinuo Pang
    Ahmed A. Suleiman
    Rheumatology and Therapy, 2022, 9 : 1587 - 1603
  • [24] Population pharmacokinetic and exposure-response analyses of guanfacine in Japanese pediatric ADHD patients
    Tsuda, Yoshiyuki
    Matsuo, Yumiko
    Matsumoto, Sayaka
    Wajima, Toshihiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (06) : 365 - 371
  • [25] EFFICACY OF RISANKIZUMAB RESCUE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND INADEQUATE RESPONSE TO RISANKIZUMAB MAINTENANCE THERAPY
    Baert, Filip J.
    Atreya, Raja
    Kakuta, Yoichi
    Long, Millie D.
    Roblin, Xavier
    Neimark, Ezequiel
    Song, Alexandra P.
    Wallace, Kori
    Kligys, Kristina
    Mallick, Madhuja
    Liao, Xiaomei
    Lim, Allen
    GASTROENTEROLOGY, 2022, 162 (07) : S967 - S967
  • [26] Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy
    Baert, F. J.
    Atreya, R.
    Kakuta, Y.
    Long, M.
    Roblin, X.
    Neimark, E.
    Song, A.
    Wallace, K.
    Kingys, K.
    Mallick, M.
    Liao, X.
    Lim, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I128 - I128
  • [27] Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors
    Wu, C-Y.
    Budha, N.
    Gao, Y.
    Castro, H.
    Nkobena, A.
    Ben, Y.
    Sahasranaman, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 182 - +
  • [28] Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
    Paik, P. K.
    Xiong, W.
    Hietala, S. F.
    Nyberg, J.
    Papasouliotis, O.
    Anziano, R.
    Berghoff, K.
    Johne, A.
    Girard, P.
    Strotmann, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S494 - S495
  • [29] Tepotinib Exposure-Response Analyses of Safety and Efficacy in Patients with Solid Tumors
    Xiong, W.
    Hietala, S.
    Nyberg, J.
    Papasouliotis, O.
    Anziano, R.
    Berghoff, K.
    Johne, A.
    Girard, P.
    Strotmann, R.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [30] Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease
    Majid, Oneeb
    Cao, Youfang
    Willis, Brian A.
    Hayato, Seiichi
    Takenaka, Osamu
    Lalovic, Bojan
    Reddy, Sree Harsha Sreerama
    Penner, Natasha
    Reyderman, Larisa
    Yasuda, Sanae
    Hussein, Ziad
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (12): : 2111 - 2123
12345